



Recombinant Human CNTF

Datasheet

Catalog Number: PR27005

Product Type: Recombinant Protein

Source: E. Coli

Amino Acid Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ala-Phe-Thr-Glu.

Description/Molecular Mass: Ciliary Neurotrophic Factor Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 199 amino acids and having a molecular mass of 22706 Dalton. Recombinant CNTF is purified by proprietary chromatographic techniques.

Protein Content: CNTF quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm using the absorbency value of 1.28 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a standard solution of CNTF Recombinant as a Reference Standard.

Biological Activity: The ED₅₀ as determined by the dose-dependant stimulation of TF-1 cells is less then 2 ng/ml, corresponding to a Specific Activity of 5 x 10 IU/mg.

Purity: Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis bySDS-PAGE.

Format: Lyophilized from a concentrated (1mg/ml) solution in water containing 5mM sodium Phosphate buffer pH=7.5 and 5mM sodium chloride.

Reconstitution: It is recommended to reconstitute the lyophilized HCNTF in sterile 18MΩ-cm H₂O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

Storage: Lyophilized Ciliary Neurotrophic Factor although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution CNTF should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RSKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

7/07v1

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail pshuster@neuromics1.com